Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P., became Amgen’s senior vice president and Chief Medical Officer in June 2023.

As Chief Medical Officer, Dr. Burton leads the enterprise Medical Affairs organization, driving strategic collaboration across all therapeutic areas within R&D and Commercial, as well as with external key opinion leaders. He also oversees the Digital Medicine and Inclusive Global Health & Impact teams, which leverage data, technology, and community engagement to improve access to medical care, clinical trials, and treatments for populations that have historically faced barriers to healthcare.

Dr. Burton’s return to Amgen followed a tenure as CMO of Moderna Therapeutics, where he led global medical strategy as well as patient safety and pharmacovigilance from 2021 to 2023. Before that, he spent 16 years at Johnson & Johnson, where his last role was Chief Global Medical Affairs Officer.

Dr. Burton has more than 20 years of biopharmaceutical industry experience, across all phases of drug discovery and development, spanning small and large molecules as well as mRNA therapeutics. He has also worked across multiple therapeutic areas, including oncology, cardiovascular and metabolic disease, and infectious diseases.

Dr. Burton is a physician trained at University of London. He received post graduate training in cardiovascular surgery, and he holds a PhD in molecular and cellular biology from Imperial College, London. He is a Member of the Royal College of Surgeons, a Fellow of the American College of Cardiology, an elected Fellow of the Royal College of Physicians, and has published extensively in clinical and digital medicine.